 |
|
|
| |
ASM/ICAAC
June 16-20
2016 Boston MA |
| |
| |
- Real-World Assessment of Renal and Bone Safety Among Patients Exposed to Tenofovir Disoproxil Fumarate-Containing Single Tablet Regimens
- (09/30/16)
- EVG, TAF, and FTC in Nanoparticles Control HIV in Humanized Mice - Written by Mark Mascolini - - (07/06/16)
- Residual Viremia More Frequent and Higher With
LPV/r Monotherapy Than Triple Therapy - Written by Mark Mascolini - - (07/06/16)
- Pitavastatin Lowers Inflammation/Activation Markers in HIV+ Over 52 Weeks - Written by Mark Mascolini - - (07/06/16)
- Over Half of NRTI Doses During Hemofiltration Too High or Too Low - Written by Mark Mascolini - - (07/06/16)
- ICAAC: Under 1% in TDF/FTC PrEP Demonstration Projects Picked Up HIV - Written by Mark Mascolini - - (07/06/16)
- Correlation Of Residual Viremia On Clinical Outcomes And Lipodystrophy Markers In The KRETA Study - - (07/06/16)
ICAAC: Under 1% in TDF/FTC PrEP Demonstration Projects Picked Up HIV - (06/30/16)
ASM/ICAAC: Tenofovir Alafenamide Has Wide Efficacious Range for Treatment of HIV-1 Infection: Pharmacokinetic-Pharmacodynamic Relationship From a Phase 3 Study - (06/24/16)
ASM/ICAAC: Enhanced Exposure of Tenofovir-Diphosphate in Peripheral Blood Mononuclear Cells by Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (06/24/16)
ASM/ICAAC: Pharmacokinetics - Pharmacodynamics of Emtricitabine/Tenofovir Alafenamide Demonstrated Wide Exposure Range Associated With Clinical Safety - (06/24/16)
ASM: Effects of Pitavastatin on Markers of Arterial Inflammation and Immune Activation in HIV Patients - (06/24/16)
ASM/ICAAC: Superior Efficacy and Improved Renal and Bone Safety After Switching From a Tenofovir Disoproxil Fumarate Regimen to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment - (06/23/16)
ASM/ICAAC: Switch From TDF Regimens to E/C/F/TAF Is Associated With Improved Bone Mineral Density, Decreased Serum PTH, and Decreased Bone Turnover Biomarkers - (06/23/16)
ASM/ICAAC: Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance - (06/23/16)
Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance [2] - (06/23/16)
ASM/ICAAC: Darunavir and Cobicistat in Older HIV-1-Infected Patients in a 48-week Phase 3 Trial - (06/22/16)
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients- (06/22/16)
ASM/ICAAC: Racial Characteristics of FTC/TDF for Pre-exposure Prophylaxis (PrEP) Users in the US - (06/22/16)
ASM: HIV-1 Seroconversion Across 17 International Demonstration Projects Using Pre-exposure Prophylaxis (PrEP) With Oral Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) - (06/22/16)
ASM/ICAAC: Tenofovir Alafenamide in Participants with Diabetes and Renal Impairment: Renal Safety Through 96 Weeks - (06/21/16)
Efficacy and Safety of Tenofovir Alafenamide in HIV-Infected Women With Renal Impairment: 96-Week Results - (06/21/16)
ASM/ICAAC: Switching from TDF to TAF in Patients with High Risk for CKD - (06/21/16)
Discovery of Bictegravir (GS-9883), a Novel, Unboosted, Once-Daily HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Improved Pharmacokinetics and In Vitro Resistance Profile - (06/20/16)
Antiviral Activity of Bictegravir (GS-9883), a Potent Next Generation HIV-1 Integrase Strand Transfer Inhibitor - (06/20/16)
Bictegravir (GS-9883), a Novel HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Optimized In Vitro Resistance Profile - (06/20/16)
Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV- (06/20/16)
Novel Integrase Strand Transfer Inhibitor Bictegravir 10 Day Monotherapy in HIV-1-Infected Patients - (06/20/16)
|
|
| |
|
|
|
|
|
|
